Ellsworth Advisors’s Novartis NVS Stock Holding History

Ellsworth Advisors’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$256K	Hold	1,695	–	–	0.04%	173
2026 Q1	$259K	Hold	1,695	–	–	0.05%	155
2025 Q4	$243K	Hold	1,695	–	–	0.05%	160
2025 Q3	$220K	Hold	1,695	–	–	0.05%	161
2025 Q2	$205K	Buy	+1,695	New	+$191K	0.05%	154

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ellsworth Advisors's NVS Position: Q2 2026 in Review

Ellsworth Advisors held its Novartis (NVS) position steady in Q2 2026 at 1,695 shares worth $256K. The position accounts for 0.04% of the portfolio, ranked #173.

Ellsworth Advisors first reported a position in NVS in Q2 2025 and has held it in 5 quarters since. The position peaked at $259K in Q1 2026. 1,614 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Ellsworth Advisors held 1,695 shares of Novartis worth $256K as of Q2 2026.
Ellsworth Advisors left its Novartis share count unchanged in Q2 2026.
Novartis made up 0.04% of Ellsworth Advisors's portfolio in Q2 2026, its #173 holding.
Ellsworth Advisors first reported a position in Novartis in Q2 2025 and has held it in 5 quarters since.
Ellsworth Advisors's Novartis position peaked at $259K in Q1 2026.
1,614 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Ellsworth Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.